Drug Search Results
More Filters [+]

Temanogrel

Alternative Names: temanogrel, apd791
Latest Update: 2023-12-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GPIIb/IIIa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Temanogrel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Scleroderma, General|Scleroderma, Diffuse|Raynaud Disease|Scleroderma, Systemic|Other

Phase 1: Healthy Volunteers|Acute Coronary Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

APD791-204

P2

Terminated

Scleroderma, Systemic|Raynaud Disease|Scleroderma, Diffuse|Scleroderma, General

2022-09-02

2020-000238-16

P2

Terminated

Unknown

2022-08-23

APD791-202

P2

Terminated

Other

2022-08-23

ID-TMG-102

P1

Terminated

Acute Coronary Syndrome

2016-04-01

22%

Recent News Events